DK0942754T3 - Konjugater anvendelige til behandlingen af prostatacancer - Google Patents

Konjugater anvendelige til behandlingen af prostatacancer

Info

Publication number
DK0942754T3
DK0942754T3 DK97946296T DK97946296T DK0942754T3 DK 0942754 T3 DK0942754 T3 DK 0942754T3 DK 97946296 T DK97946296 T DK 97946296T DK 97946296 T DK97946296 T DK 97946296T DK 0942754 T3 DK0942754 T3 DK 0942754T3
Authority
DK
Denmark
Prior art keywords
treatment
prostate cancer
conjugates useful
conjugates
useful
Prior art date
Application number
DK97946296T
Other languages
Danish (da)
English (en)
Inventor
M Garsky Victor
Dong-Mei Feng
Deborah Defeo-Jones
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9626309.0A external-priority patent/GB9626309D0/en
Priority claimed from GBGB9718160.6A external-priority patent/GB9718160D0/en
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Application granted granted Critical
Publication of DK0942754T3 publication Critical patent/DK0942754T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
DK97946296T 1996-10-30 1997-10-27 Konjugater anvendelige til behandlingen af prostatacancer DK0942754T3 (da)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US2922496P 1996-10-30 1996-10-30
GBGB9626309.0A GB9626309D0 (en) 1996-12-18 1996-12-18 Conjugates useful in the treatment of prostate cancer
US4292197P 1997-04-04 1997-04-04
GBGB9718160.6A GB9718160D0 (en) 1997-08-28 1997-08-28 Conjugates useful in the treatment of prostate cancer
PCT/US1997/019225 WO1998018493A2 (en) 1996-10-30 1997-10-27 Conjugates useful in the treatment of prostate cancer

Publications (1)

Publication Number Publication Date
DK0942754T3 true DK0942754T3 (da) 2003-08-04

Family

ID=27451580

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97946296T DK0942754T3 (da) 1996-10-30 1997-10-27 Konjugater anvendelige til behandlingen af prostatacancer

Country Status (32)

Country Link
EP (1) EP0942754B1 (de)
JP (1) JP2000509407A (de)
KR (1) KR100508199B1 (de)
AR (1) AR008907A1 (de)
AT (1) ATE239509T1 (de)
AU (1) AU726434B2 (de)
BG (1) BG64768B1 (de)
BR (1) BR9712589A (de)
CA (1) CA2268738A1 (de)
CO (1) CO4930281A1 (de)
CZ (1) CZ155599A3 (de)
DE (1) DE69721810T2 (de)
DK (1) DK0942754T3 (de)
DZ (1) DZ2333A1 (de)
EA (1) EA002066B1 (de)
EE (1) EE03858B1 (de)
ES (1) ES2196374T3 (de)
HK (1) HK1024876A1 (de)
HR (1) HRP970566A2 (de)
HU (1) HUP0000651A3 (de)
ID (1) ID21358A (de)
IL (1) IL129356A0 (de)
IS (1) IS5025A (de)
NO (1) NO992069L (de)
PE (1) PE17399A1 (de)
PL (1) PL333004A1 (de)
PT (1) PT942754E (de)
SK (1) SK57399A3 (de)
TR (1) TR199901485T2 (de)
TW (1) TW425286B (de)
WO (1) WO1998018493A2 (de)
YU (1) YU21399A (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL136167A0 (en) * 1997-12-02 2001-05-20 Merck & Co Inc Conjugates useful in the treatment of prostate cancer
CA2238257A1 (en) * 1998-05-22 1999-11-22 Universite De Montreal Endocytosis of amf-r and uses thereof in cancer therapy
EP1098666B1 (de) * 1998-07-17 2013-01-16 The United States of America, represented by the Secretary, Department of Health and Human Services Wasserlösliche arzneimittel und deren herstellungsmethode
US6174858B1 (en) 1998-11-17 2001-01-16 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
WO2000033888A2 (en) * 1998-12-11 2000-06-15 Coulter Pharmaceutical, Inc. Prodrug compounds and process for preparation thereof
GB9924759D0 (en) 1999-10-19 1999-12-22 Merck Sharp & Dohme Process for preparing peptide intermediates
EP1225918A2 (de) 1999-10-19 2002-07-31 Merck & Co., Inc. Konjugaten verwendbar bei prostata-krebs
JP2003512475A (ja) * 1999-10-27 2003-04-02 メルク エンド カムパニー インコーポレーテッド 前立腺癌の治療に有用な複合体の塩形態
MXPA02009019A (es) 2000-03-15 2003-02-12 Du Pont Pharm Co Farmacos antineoplasticos de objetivo, que se desdoblan por la peptidasa y su uso terapeutico.
WO2003079972A2 (en) * 2002-02-22 2003-10-02 New River Parmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
US20050187147A1 (en) * 2003-09-22 2005-08-25 Newman Michael J. Compositions and methods for increasing drug efficiency
CN100372862C (zh) * 2003-11-05 2008-03-05 天津和美生物技术有限公司 具有抗癌活性的阿霉素衍生物及其制备方法和应用
WO2008067495A2 (en) * 2006-11-29 2008-06-05 Rutgers, The State University Of New Jersey Chemotherapeutic conjugates and methods of use
CN101225094A (zh) * 2007-01-18 2008-07-23 天津和美生物技术有限公司 具有抗癌活性的蒽醌四环类化合物
JP5734209B2 (ja) * 2009-03-09 2015-06-17 ケイテーベー ツモルフォルシュングスゲゼルシャフト ミット ベシュレンクテル ハフツング プロドラッグ
EP3138581B1 (de) 2011-03-17 2019-01-02 The University of Birmingham Umgelenkte immuntherapie
CA2861066C (en) 2012-01-12 2024-01-02 Yale University Compounds and methods for the enhanced degradation of targeted proteins and other polypeptides by an e3 ubiquitin ligase
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
WO2016126611A1 (en) 2015-02-02 2016-08-11 The University Of Birmingham Targeting moiety peptide epitope complexes having a plurality of t-cell epitopes
ES2873846T3 (es) 2015-11-19 2021-11-04 Revitope Ltd Complementación de fragmento de anticuerpo funcional para un sistema de dos componentes para eliminación redirigida de células no deseadas
JP2023554520A (ja) 2020-12-22 2023-12-27 コビオレス エヌヴイ テトラペプチド部分を含む化合物
WO2022167664A1 (en) 2021-02-07 2022-08-11 Cobiores Nv Compounds comprising a tetrapeptidic moiety

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5866679A (en) * 1994-06-28 1999-02-02 Merck & Co., Inc. Peptides
US6143864A (en) * 1994-06-28 2000-11-07 Merck & Co., Inc. Peptides
AU708475B2 (en) * 1995-10-18 1999-08-05 Merck & Co., Inc. Conjugates useful in the treatment of benign prostatic hyperplasia

Also Published As

Publication number Publication date
HRP970566A2 (en) 1998-08-31
ES2196374T3 (es) 2003-12-16
BG103436A (en) 2000-04-28
AR008907A1 (es) 2000-02-23
SK57399A3 (en) 2000-01-18
EE9900179A (et) 1999-12-15
BG64768B1 (bg) 2006-03-31
AU5149798A (en) 1998-05-22
DZ2333A1 (fr) 2002-12-28
AU726434B2 (en) 2000-11-09
PT942754E (pt) 2003-08-29
YU21399A (sh) 2000-03-21
CO4930281A1 (es) 2000-06-27
WO1998018493A3 (en) 1998-07-23
BR9712589A (pt) 1999-10-26
EP0942754A2 (de) 1999-09-22
TR199901485T2 (xx) 1999-08-23
HUP0000651A3 (en) 2001-12-28
JP2000509407A (ja) 2000-07-25
NO992069L (no) 1999-06-30
EA199900428A1 (ru) 2000-02-28
WO1998018493A2 (en) 1998-05-07
KR100508199B1 (ko) 2005-08-17
CZ155599A3 (cs) 1999-10-13
KR20000052970A (ko) 2000-08-25
DE69721810D1 (de) 2003-06-12
NO992069D0 (no) 1999-04-29
CA2268738A1 (en) 1998-05-07
PE17399A1 (es) 1999-02-20
EP0942754B1 (de) 2003-05-07
IL129356A0 (en) 2000-02-17
ATE239509T1 (de) 2003-05-15
ID21358A (id) 1999-05-27
PL333004A1 (en) 1999-11-08
IS5025A (is) 1999-04-13
DE69721810T2 (de) 2004-03-11
HK1024876A1 (en) 2000-10-27
HUP0000651A2 (hu) 2000-06-28
EA002066B1 (ru) 2001-12-24
TW425286B (en) 2001-03-11
EE03858B1 (et) 2002-10-15

Similar Documents

Publication Publication Date Title
DK0942754T3 (da) Konjugater anvendelige til behandlingen af prostatacancer
NO994069L (no) Forbindelser for immunoterapi av prostatacancer og fremgangsmate for anvendelse derav
DK0972201T3 (da) Forbindelser til immundiagnosticering af prostatacancer og fremgangsmåder til anvendelse heraf
DK0830864T3 (da) Kombinationsbehandling til behandling af psykoser
AU1958897A (en) Egf-genistein conjugates for the treatment of cancer
PT809996E (pt) Conjugados de interferao
NO974554L (no) FremgangsmÕte for behandling av en underjordisk formasjon
TR199800436A3 (tr) Primidin türevlerinin kanserin önlenmesi için kullanilmasi.
DE69936997D1 (de) Paletteneinrichtung
ITMI990375A1 (it) Trattamento del cancro co epotiloni
NO991647D0 (no) Ledekile
ID27841A (id) Turunan-turunan biaril terapeutik
EP0926955A4 (de) Konjugate nützlich in die behandlung von prostatakarzinom
DK0925069T3 (da) Anvendelse af Cetrorelix til behandling af godartet prostatahypertrofi og prostatacancer
DK0752870T3 (da) Anvendelse af Mycobacterium til behandling af tumorer
NO20022245D0 (no) Onkolyttiske kombinasjoner for behandling av cancer
IS5035A (is) Aðferðir til varnar gegn brjóstakrabbameini
DZ2665A1 (fr) Conjugués utiles pour le traitement du cancer de la prostate.
DK1054868T3 (da) Substituerede pyridinoarylpiperaziner egnede til behandling af prostatahyperplasi
ZA9810974B (en) Conjugates useful in the treatment of prostate cancer
DK1140147T3 (da) hCG-terapi til behandling af metastatisk brystcancer
DK0964681T3 (da) Antikonvulsive derivater til behandling af psoriasis
KR970053540U (ko) 침시술용 침관
ZA979655B (en) Conjugates useful in the treatment of prostate cancer.
BR9700778A (pt) Métodos de inibição de tumores do cólon